Chugai Pharmaceutical Co., Ltd., a partner of Roche Holding, has obtained clearance from Japanese regulators to market Actemra for the treatment of rheumatoid arthritis. Roche is banking on Actemra, an approved drug for Castleman's disease, to help offset losses from an expected decline in growth of its best-selling cancer medicines. The FDA is expected to hand down its decision on the product by Sept. 21.

Related Summaries